Prochymal® + Placebo + Standard of Care for GVHD
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Graft Versus Host Disease
Conditions
Graft Versus Host Disease
Trial Timeline
Aug 17, 2006 → May 28, 2009
NCT ID
NCT00366145About Prochymal® + Placebo + Standard of Care for GVHD
Prochymal® + Placebo + Standard of Care for GVHD is a phase 3 stage product being developed by Mesoblast for Graft Versus Host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00366145. Target conditions include Graft Versus Host Disease.
What happened to similar drugs?
20 of 20 similar drugs in Graft Versus Host Disease were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00366145 | Phase 3 | Completed |
Competing Products
20 competing products in Graft Versus Host Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Prograf + Methotrexate + Cyclosporine | Astellas Pharma | Approved | 43 |
| Alefacept | Astellas Pharma | Phase 2 | 27 |
| tacrolimus | Astellas Pharma | Approved | 43 |
| Tacrolimus + Tacrolimus | Astellas Pharma | Pre-clinical | 26 |
| azathioprine + sirolimus | Astellas Pharma | Approved | 43 |
| Itolizumab + EQ001 Placebo | Biocon | Phase 3 | 32 |
| EQ001 + EQ001 Placebo | Biocon | Phase 1/2 | 32 |
| SHR0302 | Jiangsu Hengrui Medicine | Phase 1 | 29 |
| Acalabrutinib | AstraZeneca | Phase 2 | 39 |
| Aspirin + Ticagrelor | AstraZeneca | Approved | 43 |
| Sugammadex | Merck | Approved | 43 |
| Efprezimod alfa + Methotrexate + Tacrolimus + Placebo | Merck | Phase 2 | 35 |
| Ruxolitinib | Novartis | Approved | 50 |
| Imatinib Mesylate and Nilotinib | Novartis | Phase 2 | 35 |
| Prednisone + Jakavi(ruxolitinib) + Prednisone | Novartis | Phase 2 | 42 |
| PredEver | Novartis | Phase 2 | 35 |
| Lifitegrast 5% Ophthalmic Solution + Placebo | Novartis | Phase 1 | 29 |
| Cyclosporine | Novartis | Approved | 39 |
| Everolimus + Tacrolimus + Mycophenolic acid | Novartis | Approved | 39 |
| 1 + 2 | Novartis | Approved | 43 |